Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta’s $852m Summit Collaboration Could Enable DMD Drug Combinations

Oct 05 2016

• By Mandy Jackson

Related Content

DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?

Sep 25 2016

Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations

Sep 20 2016

Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?

Sep 21 2016

Related Companies

Sarepta Therapeutics, Inc.

Summit Therapeutics Inc.

Prosensa Holding N.V

BioMarin Pharmaceutical Inc.

Additional Topics

Commercial Companies Deals Strategy Neurology BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window